MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) announced it has executed an amended agreement with MIRALOGX LLC to secure worldwide exclusive rights to two investigational drug candidates, MIRA-55 and SKNY-1.

The amended agreement grants MIRA global development, commercialization, sublicensing and intellectual property enforcement rights for both programs. MIRA-55 is being developed for chronic inflammatory pain, while SKNY-1 targets obesity and addiction-related disorders.

Under the terms, MIRA receives worldwide exclusive rights under jointly owned intellectual property covering MIRA-55 and exclusive rights covering SKNY-1. The company stated the amendment does not materially modify previously disclosed core economic terms of existing license arrangements.

MIRA-55 is designed to modulate cannabinoid receptor activity while minimizing psychoactive effects. The U.S. Drug Enforcement Administration confirmed the compound is not classified as a controlled substance following scientific review. In preclinical studies, MIRA-55 demonstrated analgesic activity comparable to injected morphine in inflammatory pain models.

SKNY-1 combines pathway-selective CB1 modulation, CB2 receptor activity and selective MAO-B inhibition. Preclinical studies showed oral administration resulted in dose-dependent weight reductions and lipid normalization without significant reduction in whole-body density.

The Miami-based clinical-stage pharmaceutical company focuses on developing therapeutics for neurologic, neuropsychiatric, inflammatory and metabolic disorders. Its pipeline includes the three oral drug candidates now under global control: Ketamir-2, MIRA-55 and SKNY-1.

Neither MIRA-55 nor SKNY-1 has received FDA approval, and their safety and efficacy have not been established in humans.